Provided herein are peptide-based therapeutics that target FOXP3 and methods of use thereof to decrease the immunosuppressive effects of Tregs and inhibit immune dysregulation, while sparring inhibition of activated cytotoxic T cells, for example, in the context of anti-tumor immune responses, autoimmunity, inflammatory conditions, etc.